A total of 10 adverse events (nonserious) were reported, and all of them were resolved.
Kumar KMP, Chawla M, Sanghvi A, Sastry NG, Kotla C, Phatak S, Choudhari S 2019, 'Adherence, satisfaction, and experience with metformin 500 mg prolonged release formulationin Indian patients with type 2 diabetes mellitus: a postmarketing observational study',International Journal of General Medicinehttps://www.dovepress.com/adherence-satisfaction-and-experience-with-metformin-500-mg-prolonged--peer-reviewed-article-IJGM. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
Two nonserious adverse events were reported for two of the 84 enrolled eyes (two subjects).
Su S, Johns L, Rah MJ, Ryan R, Barr J 2015, 'Clinical performance of KeraSoft® IC in irregular corneas', Clinical Ophthalmologyhttps://www.dovepress.com/clinical-performance-of-kerasoftreg-ic-in-irregular-corneas-peer-reviewed-article-OPTH. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
Most adverse events were nonserious or not related to treatment.
Juan Carlos Barros-Tizón, María Luisa Torres, Ignacio Blanco, María Teresa Martínez, 2012, 'Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficientpatients treated with alpha-1-antitrypsin augmentation therapy', Therapeutic Advances in Respiratory Diseasehttps://doi.org/10.1177/1753465812438387. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
There were ten nonserious adverse events that occurred in more than one study subject.
P.I. Dickson, I. Kaitila, P. Harmatz, A. Mlikotic, A.H. Chen, A. Victoroff, M.B. Passage,J. Madden, S.Q. Le, D.E. Naylor 2015, 'Data from subjects receiving intrathecal laronidase for cervical spinal stenosis dueto mucopolysaccharidosis type I', Data in Briefhttp://www.sciencedirect.com/science/article/pii/S2352340915001602. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
In total 78 serious adverse events were reported in 40 patients and 77 nonserious adverse events in 34 patients.
Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S, HermansC, MacDonald K, Abraham I 2013, 'Real-world variability in ranibizumab treatment and associated clinical, quality oflife, and safety outcomes over 24 months in patients with neovascular age-relatedmacular degeneration: the HELIOS study', Clinical Ophthalmologyhttp://www.dovepress.com/real-world-variability-in-ranibizumab-treatment-and-associated-clinica-a14404. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
Nine serious adverse events and nine nonserious adverse events in 14 patients were suspected to be related to ranibizumab treatment.
Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S, HermansC, MacDonald K, Abraham I 2013, 'Real-world variability in ranibizumab treatment and associated clinical, quality oflife, and safety outcomes over 24 months in patients with neovascular age-relatedmacular degeneration: the HELIOS study', Clinical Ophthalmologyhttp://www.dovepress.com/real-world-variability-in-ranibizumab-treatment-and-associated-clinica-a14404. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
Clinical descriptions of study subjects, nonserious adverse events, individual data tables, and scoring system methods are provided.
P.I. Dickson, I. Kaitila, P. Harmatz, A. Mlikotic, A.H. Chen, A. Victoroff, M.B. Passage,J. Madden, S.Q. Le, D.E. Naylor 2015, 'Data from subjects receiving intrathecal laronidase for cervical spinal stenosis dueto mucopolysaccharidosis type I', Data in Briefhttp://www.sciencedirect.com/science/article/pii/S2352340915001602. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)